^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tyrosine kinase inhibitor

    Related drugs:
    2d
    CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov)
    P3, N=240, Recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    2d
    COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov)
    P3, N=240, Not yet recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    7d
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    10d
    A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Exelixis
    New P2 trial
    |
    zanzalintinib (XL092)
    17d
    XL092-311: A Phase 2/3 clinical trial with zanzalintinib versus everolimus (2025-521043-20-00)
    P2/3, N=172, Not yet recruiting, Exelixis Inc.
    New P2/3 trial
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    everolimus • zanzalintinib (XL092)
    19d
    Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. (PubMed, Front Immunol)
    Emerging clinical and translational data indicate that disrupting this axis can sensitize MSS-CRC to ICIs: for example, Zanzalintinib combined with Atezolizumab reported survival benefit in the STELLAR-303 trial, and dual blockade of novel checkpoints with PD-(L)1 has been associated with enhanced immune activation in solid tumors. Targeting the MDSC-Treg axis therefore represents a promising strategy to overcome immunotherapy resistance in MSS/pMMR CRC.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD73 (5'-Nucleotidase Ecto) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TLR4 (Toll Like Receptor 4) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    |
    Tecentriq (atezolizumab) • zanzalintinib (XL092)
    21d
    ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Semena (befotertinib)
    22d
    STELLAR-002: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FH (Fumarate Hydratase)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • zanzalintinib (XL092)
    1m
    Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=21, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Fumena (vorolanib)
    1m
    A Single-Arm, Single-Center Clinical Study of Vorolanib Combined with Toripalimab as First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma (ChiCTR2500111737)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P4 trial
    |
    Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)
    1m
    Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signaling. (PubMed, J Biol Chem)
    Despite advancements in anti-angiogenic cancer therapies, such as bevacizumab, late-stage tumors, including advanced melanomas, exhibit mixed clinical responses...This L-EV-mediated increase in endothelial tube formation is sensitive to the effects of sorafenib, a multi-kinase inhibitor, but not SU5416, a selective VEGF-receptor inhibitor...Finally, we show that EV subtypes have distinct effects on the acquisition of angiogenic phenotypes and their roles vary with tumor type. These findings provide new insight into the mechanisms of angiogenic therapy resistance in melanoma and demonstrate the differential functions of EV subtypes in angiogenesis across tumor types.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Avastin (bevacizumab) • sorafenib • semaxanib (SU5416)
    2ms
    A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
    P1, N=24, Recruiting, Mannkind Corporation
    New P1 trial